20 Apr Gabapentinoids – Risk of Serious Breathing Difficulty
Posted at 10:04h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the listed companies (logo’s above), would like to inform you about the risk of serious breathing difficulty associated with the use of gabapentinoids (gabapentin and pregabalin).
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
18/04/2023
File Type:
pdf
Category:
Communication To Health Care Professionals